Drugs / Emtricitabine/tenofovir disoproxil fumarate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00298363 | Apr 2006 → Apr 2011 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-10-24 | Gilead Sciences | Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens gilead.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emtricitabine/tenofovir disoproxil fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00298363 ↗ |
| Known as | FTC/TDF | “Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)” NCT00298363 ↗ |